OBJECTIVE -The prevalence of systemic hypertension is increased in patients with diabetes. In this prospective, randomized, crossover clinical trial, we assessed the antihypertensive effects of chronic intermittent intravenous insulin therapy (CHIT) on insulin-dependent diabetes mellitus (IDDM) subjects with hypertension and nephropathy by monitoring the amount of antihypertensive medication (AHM) required to maintain the blood pressure (BP) :< 140/90 mmHg.
S ystemic hypertension is a frequent complication found in both insulindependent diabetes mellitus (IDDM) and non-insulin-dependent diabetes mellitus (NIDDM) subjects and has proved to be an important risk factor for the development of microangiopathy (1, 2) and macroangiopathy (3) . The prevalence of hypertension in diabetic subjects is 1.5-2 times greater than in a matched nondiabetic population (4) . In IDDM, the prevalence of hypertension increases with the duration of the disease (5) and develops mainly in connection with the clinical emergence of nephropathy (6) . There seems to be a positive correlation between plasma glucose elevation and systolic blood pressure, raising the possibility that the metabolic disorders associated with diabetes are acting to either cause or amplify the concurrent blood pressure problem (7) . Significant reductions in systolic and diastolic blood pressure after improvement in metabolic control in diabetic subjects have been reported (8, 9) . Similarly, in streptozotocin-induced hypertensive diabetic rats, insulin treatment ameliorated the increased arterial blood pressure (BP) (10) . Conversely, in IDDM subjects studied during controlled insulin withdrawal (11) , the worsening of metabolic control was accompanied by blood pressure increases. These reports suggest that tight metabolic control in diabetic subjects may provide beneficial effects on blood pressure levels (12) .
We have recently reported the effect of a new therapeutic approachchronic intermittent intravenous insulin therapy (CHIT)-on glycemic control in IDDM subjects (13) . This new therapy seemed to have a positive effect on blood pressure levels in hypertensive IDDM subjects, and results of a pilot study in this regard have already been reported in abstract form (14) . Encouraged by these promising preliminary data, we designed a prospective, randomized, crossover clinical trial intended to assess the effects of CHIT on hypertension control as expressed by the antihypertensive medica- 5  5  120  20  Catapres-TTS-1   1  1  1  1  1   20  20  240  120  Catapres-TTS-3 tion (AHM) dosage requirements in hypertensive IDDM subjects.
RESEARCH DESIGN AND METHODS

Selection of subjects
Subjects were selected and randomized for study if they had: 1) a classical history of IDDM (i.e., early age of onset, episodes of diabetic ketoacidosis, brittle glycemic control); 2) a history of hypertension for at least 1 year and were taking conventional antihypertensive medication; 3) no clinical or laboratory evidence of secondary hypertension to any other cause except for diabetic renal disease; or 4) creatinine clearance >15 ml"" 1 • min" 1 • 1.73 m~2. Subjects were excluded from the study if they had: 1) a history of noncompliance with drug therapy; 2) severe underlying chronic disease (e.g., decompensated congestive heart failure, unstable angina pectoris, or a history of myocardial infarction within 6 months of entering the protocol); 3) a history of hypersensitivity reaction to angiotensinconverting enzyme (ACE) inhibitor peptide-like drugs, calcium channel blockers, loop diuretics, or clonidine; or 4) severe hypertension that could not be controlled with a drug combination from the selected AHM classes (see below) during the 1-to 3-month stabilization period. The clinical trial was approved by the Institutional Review Boards of the University of California, Davis; the Aoki Diabetes Research Institute, Sacramento; or Sequoia Hospital, Redwood City. All subjects gave written informed consent before enrollment into the study.
Of 41 subjects enrolled in the study, 32 completed the prerandomization stabilization period (see below). During the postrandomization period, six subjects were excluded because of noncompliance with the protocol (four noncompliant with the medication; two moved out of the area). We report 26 subjects who met all the inclusion criteria and completed the study.
Prerandomization stabilization period
Because of the potential for biological variability in the parameters to be assessed (e.g., HbA lc , systemic BP), all subjects selected for the study underwent a 1-to 3-month period of stabilization, during which optimization of glycemic control was obtained by uniformly instituting a regimen of four daily insulin injections (intensive subcutaneous insulin therapy [ISIT]), dietary instruction, and frequent home blood glucose monitoring (AccuChek II meter, Boehringer Mannheim, Indianapolis, IN). Concomitantly, the BP values were brought under control (at or just below 140/90 mmHg), by administering low to moderate doses of one AHM or a combination of AHMs from the classes listed in Table 1 . The AHMs were introduced in listed order (Table 1) as needed in each case, unless, on occasion, side effects to a drug required an alteration in the sequence or dosage. The decision to add a second, third, or fourth drug from the established list was made when the maximum dose (Table 1) of the drug used (e.g., ACE inhibitor) failed to control BP levels. We considered the lowest likely effective dose of each drug as a unit (AHM U) and used it in incremental doses as needed (e.g., 10 mg enalapril = 2 AHM U). The number of AHM units used expressed each patient's AHM requirements throughout the study. This experimental design was used to decrease the number of variables that had to be considered. All patients were seen weekly by the investigators, and appropriate insulin and AHM dosage adjustments were made.
Study parameters and methods
Because of the potential influence of dietary sodium intake, body weight changes, and level of physical activity on the control of hypertension, all subjects were initially instructed and reminded weekly to follow a mildly restricted sodium diet (6-8 g NaCl per day) and to maintain a stable body weight and level of physical activity throughout the study period. Diabetic control was assessed by monthly monitoring of HbA lc , determined by high-performance liquid chromatography (HPLC) performed on a Varian Vista 5500 HPLC system equipped with a Waters SP-5PW column (15) (nondiabetic HbA lc range 4.0-6.0%). Systemic BP was assessed by monthly 24-h ambulatory BP monitoring (every 20 min between 0600 and 2200 and every 30 min between 2200 and 0600; model 90207 [SpaceLabs, Redmond, WAI). The BP was also measured weekly with the patient in the sitting position, determined by the average of three readings taken at 10-min intervals, using the same ambulatory BP monitoring device. Serum and 24-h urine samples were collected for determinations of serum electrolytes, creat-DIABETES CARE, VOLUME 18, NUMBER 9, SEPTEMBER 1995 inine and blood urea nitrogen, creatinine clearance, and urinary protein excretion. These tests were performed at a commercial laboratory (Nichols Institute).
Postrandomization protocol
The baseline characteristics of the 26 subjects who completed the study are given in Table 2 . After randomization, all subjects continued on ISIT and their antihypertensive therapy and were seen weekly by the investigators. Appropriate adjustments were made in their ISIT and AHM dosages, with the goal of maintaining optimum glycemic control and a stable BP level for each individual patient. In addition, for the first 3 months, the subjects randomly assigned to group A underwent weekly CHIT (treatment phase). This novel therapeutic approach (13) consists of 7-10 pulses of intravenous insulin, along with oral glucose administration, during the 1st hour of a 3-h treatment; three treatments are given in a day. During these intravenous insulin pulses, systemic free insulin levels of over 200 /xIU/ml are achieved (unpublished data from previous experiments). At the end of this 3-month period, the CHIT was discontinued, and the group A subjects were crossed over into the control phase for another 3-month period. The subjects randomly assigned to group B first entered the control phase for 3 months, after which they were crossed over into the treatment phase for another 3-month period (Fig. 1) . The only procedural difference between the treatment and the control phases was the addition of weekly CHIT during the treatment phase.
Throughout the postrandomization period, the BP values were to be maintained relatively stable at the individual baseline level for each subject through appropriate adjustments in the AHM dosage. The baseline BP level was assessed by a 24-h ambulatory BP monitoring procedure performed at the end of the prerandomization period (mean 24-h BP). The number of AHM units required by each subject for controlling his or her BP levels at the end of the stabilization period (baseline BP) was considered to be the 100% AHM requirement for that subject. If a patient whose BP was controlled on X AHM U at baseline demonstrated a decline in BP during the treatment phase, the medication dosage was reduced in the reversed order of its introduction. First to be decreased was the class 4 AHM, then the class 3 AHM, 2 AHM, and last, the ACE inhibitor until the BP value reverted to baseline level. The degree of decline in the AHM requirement was expressed as percentage decline. Thus, each patient's AHM dosage requirements during the postrandomization period were compared to his or her baseline AHM requirements and expressed as a percentage change.
Statistical analysis
All results are given as means ± SE. Data were analyzed using BMDP2V, repeated measures of variance analysis. Differences were considered significant when P < 0.05. 
Pre-Randomization
RESULTS
Prerandomization stability and basal values
By the time randomization was performed, all subjects had stable BP values (average 130 ± 0.4/76 ± 0.3 mmHg) and optimized glycemic control for at least 1 month (average HbA lc = 7.4 ± 0.05%).
Postrandomization results
In group A subjects, the AHM dosage requirements for maintenance of the baseline BP levels decreased gradually, reaching a nadir during the 3rd month of the treatment phase. The decrease, averaging 47.3 ± 11%, was highly significant (P < 0.0072). After the discontinuation of CHIT, a gradual increase in the BP levels, necessitating a gradual increase in AHM dosage for maintenance of the baseline BP levels, was noted. By the 3rd month of the control phase, the AHM dose requirements had returned close to the baseline level (Fig. 2) .
The group B subjects required no significant changes in AHM dosages for maintenance of the baseline BP levels during the control phase. After the crossover into the treatment phase, a gradual decline in the AHM dosage requirements became evident by the end of the 1st month, reaching a nadir by the 3rd month of this phase. The average AHM dosage decline was on the order of 45.39 ± 11% (P < 0.0005) (Fig. 2) .
The combined average decrease in AHM dosage requirements during the treatment phase of both subject groups was 46.4% (P < 0.0001) and linear over time (P < 0.0058). The degree of decline in AHM dosage requirements was not uniform in all subjects: it was completely Table 3 -Characteristics of the two subject their AHM requirements during CHIT discontinued in 5 (19%), partially decreased in 16 (62%), and remained unchanged in 5 (19%) subjects (Table 3) . Therefore, in 21 (81%) study subjects, the AHM dosage had to be either discontinued or decreased to maintain baseline BP values during the treatment phase. No subject required an increase in the AHM dosage during the treatment phase.
Throughout the postrandomization period, the BP values were maintained relatively stable at individual baseline levels for each subject (Table 4) .
No significant differences in glycemic control, as expressed by the HbA lc measurements, were noted between the end of the stabilization period (baseline) and completion of the control and treatment phases (7.5 ± 0.06%, 7.5 ± 0.04%, and 7.4 ± 0.04%, respectively). The total daily insulin requirements, patients' body weight, hematocrit, and blood urea nitrogen, as well as creatinine clearance and urinary protein excretion, were not significantly different at the ends of the stabilization period, control phase, and treatment phase for either subject group A or B.
CONCLUSIONS -Our prospective, randomized, crossover clinical trial was designed to evaluate the effect of CHIT on the AHM dosage requirements in hyper- Data are means ± SE. Group A patients were in the treatment phase during months 1-3 and in the control phase during months 4-6. Group B patients were in the control phase during months 1-3 and in the treatment phase during months 4-6. tensive IDDM subjects. We initially considered using the change in mean arterial pressure to express the CHIT effect on hypertension control. However, we felt it would be unethical to potentially subject our diabetic patients with nephropathy to uncontrolled hypertension for several months. Therefore, we elected to bring the study patients' BP under control with AHM during the stabilization period and then express the CHIT effect on BP control through the required changes in AHM dosages.
The combined average decrease in AHM dosage requirements during the treatment phase of both subject groups was 46.4% (P < 0.0001) and linear over time (P < 0.0058). The degree of decline in AHM dosage requirements was not uniform in all subjects (Table 3) , suggesting an inverse relationship between the lowering of BP levels through CHIT and the duration of hypertension, baseline AHM dosage requirements for BP control, or the severity of diabetic nephropathy.
Analysis of other potential variables, which might have caused this improvement in our subjects' hypertension control during the treatment phase, suggested that CHIT itself is responsible for the changes observed. Throughout the postrandomization period, there were no significant differences between the degree of glycemic control (HbA lc ), body weight, daily amount of insulin administered, patients' volume status (as suggested by hematocrit and blood urea nitrogen levels), dietary caloric and sodium intake, or level of physical activity, in either subject group A or B. Similarly, the potential effect of the weekly physiciansubject interaction on the results was minimized by continuing them during both treatment and control phases for each subject. The only consistent difference in the protocol between, the treatment and control phases was the CHIT procedure itself, performed only during the treatment phase.
Theoretically, a placebo (saline solution pulses) CHIT trial period could have further strengthened the interpretation of our results. However, the use of saline instead of insulin pulses, while administering large amounts of oral glucose for several hours, would have lead to unacceptably severe hyperglycemia in our IDDM subjects. For this reason, the placebo-controlled trial was deemed unethical and was not used.
The exact mechanism by which CHIT reduces the AHA dosage requirements in hypertensive IDDM subjects remains to be determined. Increased vascular smooth muscle (VSM) tone is the hallmark of the hypertensive state in both IDDM and NIDDM (16, 17) . Human and animal studies suggest a role for insulin in the regulation of VSM tone (18) (19) (20) (21) (22) (23) (24) . Such insulin regulation of VSM function may be lost in insulinopenic states. In view of the positive effects of CHIT on hypertension control in IDDM subjects, it is possible that this therapy partially normalizes vascular reactivity, thus lowering the AHM dosage requirements.
We conclude that CHIT improves BP control as reflected by the significantly reduced AHM requirements in subjects with IDDM and hypertension, possibly through improvement in vascular reactivity. This effect represents a significant additional benefit of CHIT. Furthermore, due to its reproducibility, it could be used as a probe for studying biochemical and biological mechanisms of hypertension in diabetic subjects in vivo.
